Prostatitis

Nickel, J. Curtis

doi:10.5489/cuaj.11211

Cited by 53 publications

(43 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Resident epithelial and stromal cells express several TLRs, including TLR-4, TLR-5, TLR-7, and TLR-9, and also produce IL-1, IL-6, and IL-15 during inflammation [57]. Prostatic epithelial cells express Class II major histocompatibility complex molecules that participate in organspecific inflammation, resulting in the production of IL-6, IL-8, and CXCL10, and leukocyte recruitment [58]. Stromal cells express CD80, CD86, CD40, and CD134L and activate T lymphocytes directly.…”

Section: Cellular Component Of Prostate Inflammationmentioning

confidence: 99%

Consummated Review on Prostatitis

Sumitra

Chitra

2019

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Prostatitis is an inflammatory disease, when the prostate is vulnerable to infectious stimuli like urinary pathogens, are changes in the lifestyle leads to inflammation in the prostate gland. It is a pathological state where the swelling of prostate occur to most of the men and mainly elderly. Recently, prostatitis is a dangerous threat for men almost 50% total men population. The review comprises complete information regarding prostatitis and its related complications. The compilation of the data is about the disease from classification of prostatitis, causative agents, symptoms, treatment, mitigation, natural and alternative therapy to improve the quality of life. Awareness of this disease is not known to the majority of the population when it is left untreated identification and treatment at the right time help in increase in recovering from the pathological condition of the victim to overcome.

show abstract

Section: Cellular Component Of Prostate Inflammationmentioning

confidence: 99%

Consummated Review on Prostatitis

Sumitra

Chitra

2019

Asian J Pharm Clin Res

View full text Add to dashboard Cite

show abstract

“…As NIH-CPSI is believed to thoroughly reflect the current condition of CP from different aspects (i.e., pain or discomfort, urination, impact of symptoms, and quality of life) [49], it is suggested to use it as a primary outcome measure to monitor intervention's effects on CP patients consistently. In addition, the follow-up procedure is critical in the CP trials because CP is a chronic disease and may undergo frequent recurrence [8]. However, none of the included RCTs involved a follow-up evaluation.…”

Section: Modern Scientific Exploration Of Dbkw On Cpmentioning

confidence: 99%

“…Current research stated that combining active compounds would produce additional or even synergistic effects which are superior to a single compound, since concurrent and selective interaction may occur with multiple target proteins of a disease [68, 69]. The recent clinical practice guideline recommended using multimodal therapy (antibiotic with α -blocker, nonsteroidal anti-inflammatory drug, or 5 α -reductase-inhibitors) to manage CP [6, 8]. However, long-term applications of those drugs may lead to adverse events [70–73].…”

Section: Modern Scientific Exploration Of Dbkw On Cpmentioning

confidence: 99%

“…Conventional management for CBP and CP/CPPS includes medications (i.e., antibiotics, α -blocker, anti-inflammatory, and 5 α -reductase-inhibitors), surgery, physiotherapies, and psychotherapies [6, 7]. Recurrences are common when patients stop using medications [8]. A study which enrolled 68,675 patients pointed out that men who suffered from CP had a 30% higher probability of developing prostate cancer (PCa) than others [9].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Classic Herbal Formula Danggui Beimu Kushen Wan for Chronic Prostatitis: From Traditional Knowledge to Scientific Exploration

Hung

Yang

2018

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Chronic prostatitis (CP) is a chronic inflammation in the prostate with unsatisfactory management. Danggui Beimu Kushen Wan (DBKW) is a classic formula developed 1800 years ago for patients with difficult urination and it has been widely utilized for CP in modern days. However, scientific understanding of DBKW on CP has not been systematically reviewed. First, we searched the Encyclopedia of Traditional Chinese Medicine for the etiologies and pathogeneses of CP-like symptoms and DBKW and compared their similarities and differences from traditional Chinese medicine and conventional medicine perspectives. Then, we searched 21 electronic databases to identify potential clinical and experimental studies. Characteristics of included studies, ingredients, herb frequency, and possible mechanisms of actions were descriptively summarized. Risk of bias of randomized controlled trials (RCTs) was evaluated using the Cochrane risk of bias assessment tool. A total of 290 studies were identified. Six clinical studies, including four RCTs and two case series, and eight experimental studies were included. Clinical studies indicated that DBKW used alone or as an adjunct therapy significantly reduced the CP symptom scores and decreased the expressed prostatic secretions-pH when compared to antibiotics or α-blocker. Most RCTs have high or unclear risk of bias. Experimental studies revealed that DBKW may have effects on anti-inflammation, antibacteria, antioxidation, sex hormone regulation, and immunoregulation. DBKW demonstrated a great potential in the treatment of CP. High-quality RCTs and network pharmacological studies should be considered for future research.

show abstract

“…1). 2 Taken individually, each of these interventions has been shown to have a statistically significant, but not necessarily clinically relevant, beneficial impact on symptoms. 4 Collectively, however, use of the appropriate treatments can have a substantial benefit on symptoms and overall quality of life.…”

Section: Prostatitis Treatmentmentioning

confidence: 99%

Lower urinary tract symptoms associated with prostatitis

Nickel

2012

CUAJ

Self Cite

View full text Add to dashboard Cite

Approximately 50% to 60% of men with chronic prostatitis experience troublesome lower urinary tract symptoms (LUTS). Individual interventions yield statistically significant but minimally important improvements in clinical trials. Research has shown that categorizing patients with prostatitis by phenotype is an effective way to rationally select therapy and maximize the impact on symptom reduction and improve quality of life.

show abstract

Prostatitis

Cited by 53 publications

References 23 publications

Consummated Review on Prostatitis

Consummated Review on Prostatitis

A Classic Herbal Formula Danggui Beimu Kushen Wan for Chronic Prostatitis: From Traditional Knowledge to Scientific Exploration

Lower urinary tract symptoms associated with prostatitis

Contact Info

Product

Resources

About